期刊
NEUROBIOLOGY OF AGING
卷 32, 期 -, 页码 S37-S43出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.neurobiolaging.2011.09.009
关键词
Alzheimer's disease; Biomarker; Cognitive impairment; Dementia; fMRI; Functional magnetic resonance imaging
资金
- NIA NIH HHS [P50 AG005134, P01 AG036694, P01 AG036694-02, K24 AG035007-02, K24 AG035007, P30 AG062421, P50 AG005134-29] Funding Source: Medline
Functional magnetic resonance imaging (fMRI) is a relative newcomer in the field of biomarkers for Alzheimer's disease (AD). fMRI has several potential advantages, particularly for clinical trials, as it is a noninvasive imaging technique that does not require the injection of contrast agent or radiation exposure and thus can be repeated many times during a longitudinal study. fMRI has relatively high spatial and reasonable temporal resolution, and can be acquired in the same session as structural magnetic resonance imaging. Perhaps most importantly, fMRI may provide useful information about the functional integrity of brain networks supporting memory and other cognitive domains, including the neural correlates of specific behavioral events, such as successful versus failed memory formation. (C) 2011 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据